Satellite Symposia

Status as of 1 May 2018

WEDNESDAY, 13 JUNE 2018

18:15-19:45 Hall 3

Vindico Medical Education supported by
Bristol-Myers Squibb
Rheumatic complications of
cancer immunotherapy: a new and
emerging field in rheumatology

Chair(s):
Leonard H. Calabrese (United States)
Jan Leipe (Germany)
Xavier Mariette (France)

Introduction and pre-test 18:15
Biology of T cell exhaustion and the evolution
of immune checkpoint inhibitors 18:25
Diagnosis and management of rheumatic irAEs
from cancer immunotherapy 18:50
Clinical cases 19:15
Post-test and question and answer 19:35

18:15-19:45 Auditorium

AbbVie
RA treatment beyond the
conventional: will JAK inhibitors
disrupt our treatment paradigms?

Chair(s):
Peter Nash (Australia)

Peter Nash (Australia) 18:15
Welcome and introduction

John Isaacs (United Kingdom) 18:25
Influencing the JAK pathway: does selective
inhibition make mechanistic sense?

18:15-19:45 Elicium 2

Pfizer
Evolution or Revolution? How JAK
inhibitors are changing the standard
of care in RA

Chair(s):
Ronald van Vollenhoven (Netherlands)

Ronald van Vollenhoven (Netherlands) 18:15
Welcome and introductions

Where we are today: treatment trends in RA
from the clinician’s perspective 18:25
Eduardo Mysler (Argentina)

Proactive search: the best treatment for each patient 18:50
Ernest Choy (United Kingdom)

JAK inhibitors: novel therapies offering efficacious
options for patients with RA 18:50
Torsten Witte (Germany) 19:15
Safety and real-world data offer a wider window into
advanced therapies for patients with RA

Ronald van Vollenhoven (Netherlands) 19:40
RA therapy tomorrow: the road ahead
18:15-19:45  
**GSK**

**Leading the way towards a holistic approach to managing SLE**

**Chair:**
Munther Khamashta (United Arab Emirates)

- **Munther Khamashta (United Arab Emirates) 18:15**
  Welcome and introduction

- **Munther Khamashta (United Arab Emirates) 18:18**
  Patient and physician priorities in SLE management

- **Marta Mosca (Italy) 18:30**
  Why we shouldn’t be tired of hearing about fatigue

- **Alexandre Voskuyl (Netherlands) 19:00**
  Reducing long-term organ damage: Are we shooting for the moon?

- **Munther Khamashta (United Arab Emirates) 19:30**
  Summing up and concluding remarks

**Forum**

**Celltrion Healthcare**

**REdefining the future with InflixiMab bioSIMilAr**

**Chair(s):**
Rieke Alten (Germany)

- **Rieke Alten (Germany) 18:15**
  Welcome and introduction

- **Laurent Grange (France) 18:20**
  Perspectives on living with rheumatic diseases

- **Rieke Alten (Germany) 18:35**
  Physicians’ perspective on early introduction of biologics

- **Ki Chul Shin (Republic of Korea) 18:50**
  Drug retention of infliximab in ankylosing spondylitis: data from KOBIO

- **Rene Westhovens (Belgium) 19:05**
  Future of infliximab: introduction of the subcutaneous formulation

- **All 19:20**
  Panel discussion

18:15-19:45  
**UCB**

**The reality of risk – how are we responding to fragility fracture in rheumatology?**

**Chair(s):**
Socrates Papapoulos (Netherlands)

- **Socrates Papapoulos (Netherlands) 18:15**
  Why should we be vigilant for fragility fracture?

- **Ian Bruce (United Kingdom) 18:30**
  What are the complexities of decisions facing the rheumatologist? Clinical and behavioural perspectives

- **Ivo Vlaev (United Kingdom) 19:05**
  Improving the odds in fragility fracture: how can we act on risk factors in the rheumatology consultation?

- **Socrates Papapoulos (Netherlands) 19:20**
  How does our perception of risk influence how we make decisions in the rheumatology clinic?

- **All 19:30**
  Audience Q&A

18:15-19:45  
**IBSA**

**The treatment of OA: new concepts for an ‘old’ disease**

**Chair(s):**
Cem Gabay (Switzerland)

- **Cem Gabay (Switzerland) 18:15**
  Welcome and introduction

- **Xavier Chevalier (France) 18:20**
  Treat to target in osteoarthritis: towards a better benefit/risk ratio of oral drugs

- **Cem Gabay (Switzerland) 18:40**
  Osteoarthritis of the hand: current evidence on its management

- **Jean Dudler (Switzerland) 19:00**
  Additional analysis on CONCEPT study data

- **Chiara Schiraldi (Italy) 19:15**
  Pharmaceutical-grade chondroitin sulphate vs food supplements: are they equivalent?

- **All 19:30**
  Question and answer session

- **Cem Gabay (Switzerland) 19:40**
  Concluding remarks
**THURSDAY, 14 JUNE 2018**

### AbbVie

**Transforming developments: the dynamic face of rheumatology**

Chair(s):
Ferry Breedveld (Netherlands)

**Ferry Breedveld (Netherlands) 08:15**
Welcome and introduction
Transforming treatments: how TNF inhibitors led the field in the biologic revolution

**Boulos Haraoui (Canada) 08:30**
Transforming standards: treat to target and the PASSIONate revolution

**Wouter Bos (Netherlands) 08:45**
Transforming outcomes: the role of patients in assessing their own disease

**Lisa Olson (United States) 09:05**
Transforming targets: drug discovery and development

All 09:25
Panel discussion and Q&A

### Novartis

**Making the invisible visible: the impact of IL-17A inhibition in psoriatic arthritis**

Chair(s):
Dafna Gladman (Canada)

**Dafna Gladman (Canada) 08:15**
Welcome and introductions

**Georg Schett (Germany) 08:20**
Enthesitis: the link between the skin and joints in PsA

**Laura Coates (United Kingdom) 08:40**
A 360 overview on the evolving unmet needs in PsA

**Philip Conaghan (United Kingdom) 08:55**
Insights into PsA from modern imaging

**Philip Mease (United States) 09:10**
GRAPPA treatment recommendations: are they met with IL-17A inhibition?

All 09:30
Panel discussion and conclusions

### Lilly

**IL-17A inhibition: optimising the PsA management**

Chair(s):
Michael Nurmohamed (Netherlands)

**Michael Nurmohamed (Netherlands) 08:15**
Welcome and introduction

**Helena Marzo-Ortega (United Kingdom) 08:20**
Is the management of patients with PsA optimal?

**Frank Behrens (Germany) 08:35**
Overview of ixekizumab benefits and safety results

**Diamant Thaçi (Germany) 08:50**
PsA management in the real world: the rheumatologist and dermatologist perspective

All 09:20
Panel discussion

**Michael Nurmohamed (Netherlands) 09:30**
Summary and symposium close

### Roche

**Journey from clinical trials to patient care**

Chair(s):
Ernest Choy (United Kingdom)

**Ernest Choy (United Kingdom) 08:15**
Welcome & introduction

**Ernest Choy (United Kingdom) 08:20**
Exploring the value of real-world evidence (RWE)

**Deborah Symmons (United Kingdom) 08:30**
Confidence in treating the at-risk and elderly population

**Fabrizio de Benedetti (Italy) 08:50**
Advancing knowledge of the paediatric population

**Frank Buettger (Germany) 09:10**
Optimising the use of glucocorticoids in clinical practice

**Ernest Choy (United Kingdom) 09:30**
Summary

**All Faculty 09:35**
Question & answer session
**Biogen**

**Anti-TNF in rheumatic diseases: inventory and outlook**

**Chair(s):**
- Peter Taylor (United Kingdom)

**Peter Taylor (United Kingdom) 08:15**
Opening, intro & overview: the treatment landscape in RA

**Raj Sengupta (United Kingdom)**
Preparing a switch: the perfect time to re-evaluate the clinical status of patients with RA/AS

**Paul Enck (Germany)**
Preparing a switch: the perfect time to re-evaluate the patient’s psychosocial status

**Juergen Braun (Germany)**
Successful switching: shared decision making with the patient is critical

**Glenn Haugeberg (Norway)**
Post-switch patient follow-up in busy daily clinical practice - opportunities and challenges of remote patient monitoring

**All 09:40**
Summary and conclusion

---

**Menarini**

**Multimodal approach for acute pain in rheumatology - a new paradigm targeting multiple mechanisms**

**Chair(s):**
- Serge Perrot (France)

**Serge Perrot (France) 08:15**
Introduction

**Stefano Coaccioli (Italy) 08:30**
Low back pain and osteoarthritis: from clinical features to complex mechanisms

**Serge Perrot (France) 08:50**
Multimodal approach, a step forward in the current therapeutic strategy

**Magdi Hanna (United Kingdom) 09:10**
Rationale of the new oral fixed dose combination of dexketoprofen/Tramadol in targeting multiple mechanisms of moderate to severe acute pain

**Discussion and final remarks 09:30**

---

**Amgen**

**Ready for the next biosimilar? Key stakeholder insights to guide choice**

**Chair(s):**
- Thierry Thomas (France)
- Fernando Pérez-Ruiz (Spain)

**Thierry Thomas (France) 08:15**
Welcome and introduction

**Murray Aitken (United States) 08:25**
Assessing biosimilar uptake and use: a marketplace evaluation

**Fernando Pérez-Ruiz (Spain) 08:45**
Clinical perspectives: what to consider when selecting the next anti-TNF biosimilar

**Alison Kent (United Kingdom) 09:10**
Patient perspectives on anti-TNF biosimilars: understanding attitudes, beliefs and expectations

**All 09:30**
Panel discussion

**Fernando Pérez-Ruiz (Spain) 09:40**
Closing remarks
### 17:30-19:00 Auditorium

#### AbbVie
**Solving the patient puzzle: a pragmatic approach to SpA management**

**Chair(s):**
Georg Schett (Germany)

**Georg Schett (Germany)**
17:30
Welcome and introduction
The many faces of SpA: how does inflammation lead to multifaceted disease?

**Denis Poddubnyy (Germany)**
17:45
Disease progression: under control or still a cause for concern?

**Philip Mease (United States)**
18:05
Optimising long-term treatment: lessons from clinical practice

**Dirk Elewaut (Belgium)**
18:25
Integrated care: a practical approach to patient management

**All**
18:45
Panel discussion and Q&A

### 17:30-19:00 Hall 7.2

#### Pfizer
**How to detect and treat unresolved symptoms in the patient with psoriatic arthritis**

**Chair(s):**
Désirée van der Heijde (Netherlands)

**Désirée van der Heijde (Netherlands)**
17:30
Welcome and introductions

**Laure Gossec (France)**
17:35
Diagnostic ‘hot spots’: defining targets, detecting patients’ symptoms

**Enrique Soriano (Argentina)**
17:55
New products, new opportunities in PsA

**Frank Behrens (Germany)**
18:20
Optimising treatments: the physician and nurse practitioner partnership

**Désirée van der Heijde (Netherlands)**
18:40
Audience Q&A/panel discussion summary and close

### 17:30-19:00 Forum

#### Sanofi Genzyme
**The challenges of multi-morbidities in RA: IL-6 and chronic inflammation**

**Chair(s):**
Peter Taylor (United Kingdom)

**Peter Taylor (United Kingdom)**
17:30
Meeting the challenge of multi-morbidities in RA

**Michael Nurmohamed (Netherlands)**
17:40
Multi-morbidities associated with RA: defining the systemic manifestations of the disease

**Ernest Choy (United Kingdom)**
17:55
The multi-faceted role of IL-6 in RA and other RA-associated conditions

**Mark Genovese (United States)**
18:15
The effects of IL-6R blockade inside and outside the RA joint

**All**
18:35
Moderated discussion with faculty and audience Q&A

**Peter Taylor (United Kingdom)**
18:55
Close

### 17:30-19:00 Amtrium

#### Janssen
**A practical guide to new treatments in psoriatic arthritis and psoriasis**

**Chair(s):**
Dennis McGonagle (United Kingdom)

**Dennis McGonagle (United Kingdom)**
17:30
Welcome and introduction

**Costantino Pitzalis (United Kingdom)**
17:35
Pathophysiology of joint and skin diseases and implications for treatment

**Costantino Pitzalis (United Kingdom)**
17:55
Lessons from the skin: therapeutic options for psoriasis in clinical practice

**Dennis McGonagle (United Kingdom)**
18:20
Lessons from the joint: therapeutic options for psoriatic arthritis in clinical practice

**All**
18:45
Q&A

Conclusions and close of meeting 18:55
17:30-19:00 Emerald

**Bristol-Myers Squibb**

**Modulating the wayward T cell: the new horizon in autoimmunity and cancer**

**Chair(s):**
Leonard Calabrese (United States)

**Leonard Calabrese (United States)** 17:45
Welcome and introduction

**Leonard Calabrese (United States)** 17:47
T-cell co-stimulation in health and disease

**Roberto Caporali (Italy)** 18:12
T cell-B cell communication in autoimmune diseases, with a focus on RA

**Christian Blank (Netherlands)** 18:37
Expanding our understanding of T-cell modulation through learnings from cancer

**All** 19:02
Panel discussion and Q&A

17:30-19:00 E106/E107

**Samsung Bioepis**

**The era of biosimilars: reshaping the healthcare environment**

**Chair(s):**
Josef Smolen (Austria)

**Josef Smolen (Austria)** 17:30
Welcome and introduction

**Josef Smolen (Austria)** 17:40
Anti-TNF biosimilars in rheumatology

**João Gonçalves (Portugal)** 17:55
Reinvestigating biologics quality excellence

**Mark Quinn (United Kingdom)** 18:10
Biosimilar adoption: improving rheumatology services for patients

**Fabrizio Benedetti (Italy)** 18:25
Understanding the nocebo effect

**All** 18:40
Q&A

**Josef Smolen (Austria)** 18:50
Closing

FRIDAY, 15 JUNE 2018

08:15-09:45 Auditorium

**Lilly**

**Challenging the rheumatoid arthritis treatment standards with JAK inhibitors**

**Chair(s):**
Désirée van der Heijde (Netherlands),
Mark C. Genovese (United States)

**Désirée van der Heijde (Netherlands)** 08:15
Welcome and introduction

**Mark C. Genovese (United States)** 08:20
JAK inhibitors - are they all the same?

**Paul Emery (United Kingdom)** 08:35
JAK inhibitor baricitinib: how is it different from the standard of care (anti-TNF)?

**Ronald van Vollenhoven (Netherlands)** 08:50
JAK inhibitors position in the treatment algorithm of rheumatoid arthritis

**Ulf Müller-Ladner (Germany)** 09:05
JAK inhibitors in clinical practice

**Désirée van der Heijde (Netherlands)** 09:20
Mark C. Genovese (United States)
Panel discussion and Q&A

Symposium close 09:45

08:15-09:45 Elicium 2

**Novartis**

**IL-17A inhibition in axial spondyloarthritis: new insights and implications for clinical practice**

**Chair(s):**
Filip van den Bosch (Belgium)

**Filip van den Bosch (Belgium)** 08:15
Welcome and introductions

**Filip van den Bosch (Belgium)** 08:20
Axial spondyloarthritis: what matters to a patient?

**Atul Deodhar (United States)** 08:35
Clinical intervention in axial spondyloarthritis: why, when and how?

**Rik Lories (Belgium)** 08:55
Underlying pathophysiology of axial spondyloarthritis: clinical assessments and implications

**Xenofon Baraliakos (Germany)** 09:10
IL-17A inhibition in axial spondyloarthritis: current and future perspectives

**All** 09:30
Panel discussion and conclusions
### Forum 08:15-09:45

**Integritas supported by Gilead Sciences, Inc.**

**Clinical issues in rheumatoid arthritis: discussions and debates on the evolving roles of targeted synthetic DMARDs**

**Chair(s):**
Rieke Alten (Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>Welcome and pre-activity questionnaire Rieke Alten (Germany)</td>
</tr>
<tr>
<td>08:20</td>
<td>Pathophysiology: a focus on JAK enzymes Josef Smolen (Austria)</td>
</tr>
<tr>
<td>08:35</td>
<td>Long-term assessment of patient with RA: understanding treatment targets as a foundation for therapeutic tailoring Joel Kremer (United States)</td>
</tr>
<tr>
<td>08:55</td>
<td>Targeted synthetic DMARDs in the treatment of RA Rieke Alten (Germany)</td>
</tr>
<tr>
<td>09:15</td>
<td>Case study panel discussion: putting the evidence to practice All</td>
</tr>
<tr>
<td>09:30</td>
<td>Post-activity questionnaire and Q&amp;A session All</td>
</tr>
</tbody>
</table>

### Emerald 08:15-09:45

**Celgene**

**Towards a targeted approach in psoriatic arthritis with PDE4 inhibition**

**Chair(s):**
Laure Gossec (France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>Opening statement Laure Gossec (France)</td>
</tr>
<tr>
<td>08:20</td>
<td>Guidelines in evolution and their applicability in treatment decisions Laure Gossec (France)</td>
</tr>
<tr>
<td>08:35</td>
<td>Evidence from homogeneous clinical trials for a diverse patient population – the challenge in PsA patient care Frank Behrens (Germany)</td>
</tr>
<tr>
<td>09:00</td>
<td>Optimising the clinical utility of PDE4 inhibition Audience Q&amp;A Philip J. Mease (United States)</td>
</tr>
<tr>
<td>09:20</td>
<td>Summary and close Laure Gossec (France)</td>
</tr>
</tbody>
</table>

### Amtrium 08:15-09:45

**UCB**

**Axial spondyloarthritis in 2018: new data, less compromise?**

**Chair(s):**
Martin Rudwaleit (Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>Welcome and introduction from the symposium chair Martin Rudwaleit (Germany)</td>
</tr>
<tr>
<td>08:20</td>
<td>Diagnostic delay, establishing disease control and starting a family Lianne Gensler (United States)</td>
</tr>
<tr>
<td>08:45</td>
<td>The right management strategy for the right patient Maxime Dougados (France)</td>
</tr>
<tr>
<td>09:05</td>
<td>Taking control of structural damage progression and exploring new horizons Denis Podubnyy (Germany)</td>
</tr>
<tr>
<td>09:25</td>
<td>Wrap-up and conclusion Martin Rudwaleit (Germany)</td>
</tr>
<tr>
<td>09:40</td>
<td>Question and answer session moderated by the symposium chair All</td>
</tr>
</tbody>
</table>

### E106/E107 08:15-09:45

**Boehringer Ingelheim**

**Interstitial lung disease in autoimmune rheumatic diseases – moving towards better patient care**

**Chair(s):**
Frank van den Hoogen (Netherlands)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>How relevant is ILD in autoimmune rheumatic diseases? Frank van den Hoogen (Netherlands)</td>
</tr>
<tr>
<td>08:25</td>
<td>How should we diagnose and monitor ILD? Athol Wells (United Kingdom)</td>
</tr>
<tr>
<td>08:45</td>
<td>Treatment of ILD in autoimmune rheumatic diseases Christopher Denton (United Kingdom)</td>
</tr>
<tr>
<td>09:05</td>
<td>Future perspectives on the treatment of fibrosis Jörg Distler (Germany)</td>
</tr>
<tr>
<td>09:25</td>
<td>Questions and answers All</td>
</tr>
</tbody>
</table>
**17:30-19:00**  
**Auditorium**

**Pfizer**

**Unraveling chronic pain: from defining to modulating**

**Chair(s):**  
Francis Berenbaum (France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>Welcome and faculty introductions</td>
<td>Francis Berenbaum (France)</td>
</tr>
<tr>
<td>17:35</td>
<td>Defining the humanistic and societal burden of chronic pain</td>
<td>Francis Berenbaum (France)</td>
</tr>
<tr>
<td>17:55</td>
<td>Overview of pain pathways and mediators of pain sensitization</td>
<td>Martin Koltzenburg (United Kingdom)</td>
</tr>
<tr>
<td>18:20</td>
<td>Current and future approaches to modulate chronic pain</td>
<td>Richard Langford (United Kingdom)</td>
</tr>
<tr>
<td>18:45</td>
<td>All Panel discussion and Q&amp;A</td>
<td>Francis Berenbaum (France)</td>
</tr>
<tr>
<td>18:55</td>
<td>Closing remarks</td>
<td>Francis Berenbaum (France)</td>
</tr>
</tbody>
</table>

---

**17:30-19:00**  
**Amtrium**

**Rheumatology Today**

**Highlights of EULAR 2018**

**Chair(s):**  
Matthias Schneider (Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>Welcome and introduction</td>
<td>Peer M. Aries (Germany)</td>
</tr>
<tr>
<td>17:40</td>
<td>Current options: limitations of current treatment in lupus</td>
<td>Xenofon Baraliakos (Germany)</td>
</tr>
<tr>
<td>17:40</td>
<td>How to assess lupus in clinical care</td>
<td>Frank Behrens (Germany)</td>
</tr>
<tr>
<td>17:40</td>
<td>Biologics: what’s coming next?</td>
<td>Christof Iking-Konert (Germany)</td>
</tr>
<tr>
<td>17:40</td>
<td>Current options: limitations of current treatment in lupus</td>
<td>Christof Specker (Germany)</td>
</tr>
<tr>
<td>17:40</td>
<td>How to assess lupus in clinical care</td>
<td>Torsten Witte (Germany)</td>
</tr>
<tr>
<td>17:40</td>
<td>Presentation of six trials presented at EULAR 2018 featuring the following topics:</td>
<td></td>
</tr>
</tbody>
</table>
- Axial spondylarthritis  
- Biologica monotherapy  
- Collagenoses  
- Novelties in RA treatment  
- Psoriatic arthritis  
- Vasculitis |

---

**17:30-19:00**  
**Forum**

**RMEI supported by Sanofi Genzyme & Regeneron**

**Global perspectives in RA: the role of new biologics for optimal management**

**Chair(s):**  
Paul Emery (United Kingdom)

**Speakers:**  
Paul Emery (United Kingdom)  
Leonard H. Calabrese (United States)  
Josef F. Smolen (Austria)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>Introductions and overview of panel topics</td>
<td>Paul Emery (United Kingdom)</td>
</tr>
<tr>
<td>17:40</td>
<td>The patient with RA who fails to respond</td>
<td>Faculty Panel Discussion #1</td>
</tr>
<tr>
<td>18:05</td>
<td>The patient with RA who becomes non-responsive</td>
<td>Faculty Panel Discussion #2</td>
</tr>
<tr>
<td>18:30</td>
<td>The patient with poor response and comorbidities</td>
<td>Faculty Panel Discussion #3</td>
</tr>
<tr>
<td>18:55</td>
<td>Summary remarks</td>
<td>Paul Emery (United Kingdom)</td>
</tr>
</tbody>
</table>

---

**17:30-19:00**  
**Emerald**

**Janssen**

**Lupus: now and in the future**

**Chair(s):**  
David Isenberg (United Kingdom)  
Ronald van Vollenhoven (Netherlands)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>Welcome and introduction</td>
<td>David Isenberg (United Kingdom)</td>
</tr>
<tr>
<td>17:40</td>
<td>Current options: limitations of current treatment in lupus</td>
<td>Angela Tincani (Italy)</td>
</tr>
<tr>
<td>18:00</td>
<td>How to assess lupus in clinical care</td>
<td>Ronald van Vollenhoven (Netherlands)</td>
</tr>
<tr>
<td>18:20</td>
<td>Biologics: what’s coming next?</td>
<td>David Isenberg (United Kingdom)</td>
</tr>
</tbody>
</table>
| 18:40 | Panel discussion | Elisabet Svenungsson (Sweden)  
Angela Tincani (Italy)  
Ronald van Vollenhoven (Netherlands) |
| 18:55 | Conclusions and close of meeting | Angela Tincani (Italy)  
Ronald van Vollenhoven (Netherlands) |
Menarini

Hyperuricemia with deposition: a multisystemic disease

Chair(s):
Fernando Perez-Ruiz (Spain)

Fernando Perez-Ruiz (Spain)
Introduction

Claudio Borghi (Italy)
Hyperuricemia with deposition: a cardio metabolic disorder

Leonardo Punzi
Interaction between hyperuricemia with deposition and rheumatic diseases

Fernando Perez-Ruiz (Spain)
Hyperuricemia with deposition: the importance of adherence to treatment

Fernando Perez-Ruiz (Spain)
Summary and meeting close